DNAY - Codex DNA acquires Eton Bioscience for ~$13M
Codex DNA (NASDAQ:DNAY) has acquired Eton Bioscience for approximately $13M in cash. The acquisition is expected to be slightly dilutive to Codex DNA’s earnings per share in 2022, and accretive thereafter. “Together with the Eton team, we will be able to accelerate our BioXp system growth strategy within the synthetic biology market,” said Todd R. Nelson, PhD, CEO of Codex DNA. “This acquisition will allow our combined company to increase its commercial reach, deliver more robust services with broader customer applications, improve the quality and cost of certain raw materials, and support our highly strategic enzymatic DNA synthesis product development program.”
For further details see:
Codex DNA acquires Eton Bioscience for ~$13M